08/04/22 8:00 AMNasdaq : SBFM, SBFMW earningslow floatSunshine Biopharma Files Its Second Quarter Report With the SECSunshine Biopharma, Inc. (NASDAQ: “SBFM” and “SBFMW”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviralRHEA-AIneutral
07/28/22 8:10 AMNasdaq : SBFM, SBFMW low floatSunshine Biopharma Increases Support for Anti-Coronavirus Collaborative Research With the University of ArizonaSunshine Biopharma Inc. (NASDAQ: “SBFM” and SBFMW) (the “Company” or “Sunshine Biopharma”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs today announced that it has agreed to provideRHEA-AIneutral
04/28/22 4:50 PMNasdaq : SBFM, SBFMW low floatSunshine Biopharma, Inc. Announces Closing of $19.5 Million Private Placement Priced At-the-MarketSunshine Biopharma, Inc. (NASDAQ: “SBFM” and “SBFMW”) (the “Company” or “Sunshine Biopharma”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today closed its previously announcedRHEA-AIneutral
04/26/22 12:41 AMNasdaq : SBFM, SBFMW low floatSunshine Biopharma, Inc. Announces Pricing of $19.5 Million Private Placement Priced At-the-MarketSunshine Biopharma, Inc. (NASDAQ: “SBFM” and “SBFMW”) (the “Company” or “Sunshine Biopharma”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it entered into aRHEA-AIneutral
04/25/22 8:00 AMNasdaq : SBFM, SBFMW low floatSunshine Biopharma Files Patent Application Covering Recently Announced mRNA Molecules Found To Be Effective At Destroying Multidrug Resistant Cancer CellsSunshine Biopharma, Inc. (NASDAQ: “SBFM” and “SBFMW”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has filed a provisional patent application in the UnitedRHEA-AIneutral
04/05/22 8:00 AMNasdaq : SBFM, SBFMW low floatSunshine Biopharma’s Newly Designed mRNA Molecules Prove Effective Against Multidrug Resistant Cancer CellsSunshine Biopharma, Inc. (NASDAQ: “SBFM” and “SBFMW”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs,RHEA-AIneutral
03/14/22 6:12 PMNasdaq : SBFM, SBFMW low floatSunshine Biopharma, Inc. Announces Closing of $8.0 Million Private Placement Priced At-the-MarketSunshine Biopharma, Inc. (NASDAQ: “SBFM” and “SBFMW”) (the “Company” or “Sunshine Biopharma”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today closed its previously announcedRHEA-AIneutral
03/10/22 9:17 AMNasdaq : SBFM, SBFMW low floatSunshine Biopharma, Inc. Announces Pricing of $8.0 Million Private Placement Priced At-the-MarketSunshine Biopharma, Inc. (NASDAQ: “SBFM” and “SBFMW”) (the “Company” or “Sunshine Biopharma”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it entered into aRHEA-AIneutral
02/25/22 8:00 AMNasdaq : SBFM, SBFMW low floatSunshine Biopharma Expands Anti-Coronavirus Drug Development Program By Signing A Collaboration Agreement With The University Of ArizonaSunshine Biopharma Inc. (NASDAQ: “SBFM” and SBFMW) (the “Company” or “Sunshine Biopharma”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs today announced that it has entered into anRHEA-AIneutral
02/17/22 10:40 AMNasdaq : SBFM, SBFMW offeringlow floatAegis Capital Corp. acted as Sole Bookrunner on an Uplist of an $8 Million Underwritten Public Offering for Sunshine Biopharma Inc. (NASDAQ: SBFM; SBFMW)Aegis Capital Corp. acted as Sole Bookrunner on an Uplist of an $8 Million Underwritten Public Offering for Sunshine Biopharma Inc. (NASDAQ:SBFM;RHEA-AIneutral
